Vistagen announces european patent office intention to grant new ph80 nasal spray patent for the treatment of migraine

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (cns) disorders, today announced that the european patent office (epo) issued an intention to grant a patent for the treatment of migraine by nasal administration of ph80 nasal spray, one of the company's five rapid-onset investigational neuroactive pher.
VTGN Ratings Summary
VTGN Quant Ranking